The First Decade of Advanced Cell Therapy Clinical Trials Using Perinatal Cells (2005–2015)

Couto, Pedro Silva; Bersenev, Alexey; Verter, Frances

doi:10.2217/rme-2017-0066

Cited by 23 publications

(26 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent review of clinical trials employing perinatal tissue-derived products in advanced cell therapy identified 281 clinical studies registered between 2005 and 2015, and acquired neurological conditions or disorders was the second most common category of diagnosis behind trials in hematology or oncology with manipulated cell types [21]. Of more than 500 cord blood units released for clinical application from our institution, 80% have gone to clinical trials or experimental uses in regenerative medicine, with the vast majority of those indications being neurological injuries sustained at or around the time of birth or diagnosis associated with said injuries (Figure 2).…”

Section: Newborn Stem Cells In Transplant and Regenerative Medicinmentioning

confidence: 99%

The Future State of Newborn Stem Cell Banking

Brown¹,

Rao

Brown³

2019

JCM

View full text Add to dashboard Cite

Newborn stem cell banking began with the establishment of cord blood banks more than 25 years ago. Over the course of nearly three decades, there has been considerable evolution in the clinical application of stem cells isolated from newborn tissues. The industry now finds itself at an inflection point as personalized medicine and regenerative medicine continue to advance. In this review, we summarize our perspective on newborn stem cell banking in the context of the future potential that stem cells from perinatal tissues are likely to play in nascent applications. Specifically, we describe the relevance of newborn stem cell banking and how the cells stored can be utilized as starting material for the next generation of advanced cellular therapies and personalized medicine.

show abstract

Section: Newborn Stem Cells In Transplant and Regenerative Medicinmentioning

confidence: 99%

The Future State of Newborn Stem Cell Banking

Brown¹,

Rao

Brown³

2019

JCM

View full text Add to dashboard Cite

show abstract

“…Indeed, it is by merit of unique immune modulatory features, rather than differentiation, that placenta-derived MSC show promise for a wide range of regenerative medicine applications. Fast-forward to today there are over 20 clinical trials (excluding trials with unknown status) evaluating “placenta derived cells” and “placenta MSC” registered on the NIH Clinical Trials website (https://clinicaltrials.gov/) (Couto et al, 2017). The published or current clinical trials are either Phase I, II, or III and include a variety of inflammatory disorders, such as pulmonary idiopathic fibrosis (Chambers et al, 2014), peripheral artery disease, Crohn's disease (Mayer et al, 2013; Melmed et al, 2015), multiple sclerosis (Lublin et al, 2014), diabetes (Jiang et al, 2011), ischemic stroke, pulmonary sarcoidosis (Baughman et al, 2015), active rheumatoid arthritis, and muscle injury due to hip arthroplasty (Winkler et al, 2018).…”

Section: Shaping the Futurementioning

confidence: 99%

Shaping the Future of Perinatal Cells: Lessons From the Past and Interpretations of the Present

Silini

Masserdotti

Papait

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Since their discovery and characterization, mesenchymal stromal cells (MSC) have been a topic of great interest in regenerative medicine. Over the last 10 years, detailed studies investigated the properties of MSC from perinatal tissues and have indicated that these cells may represent important tools for restoring tissue damage or promoting regeneration and repair of the tissue microenvironment. At first, perinatal tissue-derived MSC drew attention due to their potential differentiation capacities suggested by their early embryological origin. It is nowadays accepted that perinatal tissue-derived MSC are promising for a wide range of regenerative medicine applications because of their unique immune modulatory properties, rather than their differentiation ability. As a matter of fact, the activation and function of various cells of the innate and adaptive immune systems are suppressed and modulated by MSC from different perinatal tissues, such as human term placenta. However, the mechanisms by which they act on immune cells to facilitate tissue repair during pathological processes remain to be thoroughly elucidated to develop safe and efficient therapeutic approaches. In addition to immune modulatory ability, several other peculiar characteristics of placenta MSC, less explored and/or more debated, are being investigated. These include an understanding of the anti-microbial properties and the role of placental MSC in tumor progression. Moreover, a thorough investigation on preparation methods, bioactive factors, mechanisms of action of the cell secretome, and the development of potency assays to predict clinical efficacy of placenta MSC and their products, are necessary to provide a solid basis for their clinical application.

show abstract

“…We now know that perinatal derivatives are promising for a wide range of regenerative medicine applications due to their differentiation capabilities but mainly due to their unique immune modulatory properties. As a matter of fact, many preclinical studies and initial clinical trials have demonstrated that perinatal derivatives may represent important tools for restoring tissue damage or promoting regeneration and repair of the tissue microenvironment (Caruso et al, 2012;Cirman et al, 2014;Jerman et al, 2014;Silini et al, 2015;Joerger-Messerli et al, 2016;Magatti et al, 2016;Couto et al, 2017;Silini et al, 2017;Bollini et al, 2018;Pogozhykh et al, 2018;Ramuta and Kreft, 2018;Verter et al, 2018;Silini et al, 2019;Ramuta et al, 2020). The term "perinatal" refers to birthassociated tissues that are obtained from term placentas and fetal annexes and more specifically refers to the amniotic/amnionic (herein referred to as amniotic due to its prevalence in literature) membrane, chorionic membrane, chorionic villi, umbilical cord (including Wharton's jelly), the basal plate (including maternal and fetal cells), and the amniotic fluid.…”

Section: Introductionmentioning

confidence: 99%

Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature

Silini

Pietro

Lang-Olip

et al. 2020

Front. Bioeng. Biotechnol.

102

View full text Add to dashboard Cite

Progress in the understanding of the biology of perinatal tissues has contributed to the breakthrough revelation of the therapeutic effects of perinatal derivatives (PnD), namely birth-associated tissues, cells, and secreted factors. The significant knowledge acquired in the past two decades, along with the increasing interest in perinatal derivatives, fuels an urgent need for the precise identification of PnD and the establishment of updated consensus criteria policies for their characterization. The aim of this review is not to go into detail on preclinical or clinical trials, but rather we address specific issues that are relevant for the definition/characterization of perinatal cells, starting from an understanding of the development of the human placenta, its structure, and the different cell populations that can be isolated from the different perinatal tissues. We describe where the cells are located within the placenta and their cell morphology and phenotype. We also propose nomenclature for the cell populations and derivatives discussed herein. This review is a joint effort from the COST SPRINT Action (CA17116), which broadly aims at approaching consensus for different aspects of PnD research, such as providing inputs for future standards for the processing and in vitro characterization and clinical application of PnD.

show abstract

The First Decade of Advanced Cell Therapy Clinical Trials Using Perinatal Cells (2005–2015)

Cited by 23 publications

References 33 publications

The Future State of Newborn Stem Cell Banking

The Future State of Newborn Stem Cell Banking

Shaping the Future of Perinatal Cells: Lessons From the Past and Interpretations of the Present

Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature

Contact Info

Product

Resources

About